Health Rise Pharma India Profile
Key Indicators
- Authorised Capital ₹ 4.00 M
as on 16-12-2024
- Paid Up Capital ₹ 4.00 M
as on 16-12-2024
- Company Age 9 Year, 9 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 7.60 M
as on 16-12-2024
- Revenue -64.14%
(FY 2022)
- Profit 254.64%
(FY 2022)
- Ebitda -279.48%
(FY 2022)
- Net Worth 181.73%
(FY 2022)
- Total Assets 2.49%
(FY 2022)
About Health Rise Pharma India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 4.00 M and a paid-up capital of Rs 4.00 M.
The company currently has active open charges totaling ₹7.60 M.
The Key Managerial Personnel (KMP) at Health Rise Pharma India Private Limited India is Parveen Mangla as CFO. Sachin Popli, Lalita, and Parveen Mangla serve as directors at the Company.
- CIN/LLPIN
U74900HR2015PTC054933
- Company No.
054933
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Mar 2015
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Faridabad, Haryana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Health Rise Pharma India?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Parveen Mangla  | CFO | 18-Feb-2021 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sachin Popli | Director | 19-Mar-2015 | Current |
| Lalita | Director | 19-Mar-2015 | Current |
Financial Performance of Health Rise Pharma India.
Health Rise Pharma India Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 64.14% decrease. The company also saw a substantial improvement in profitability, with a 254.64% increase in profit. The company's net worth Soared by an impressive increase of 181.73%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Health Rise Pharma India?
In 2022, Health Rise Pharma India had a promoter holding of 25.00% and a public holding of 75.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 30 Nov 2018 | ₹5.80 M | Open |
State Bank Of India Creation Date: 30 Mar 2016 | ₹1.80 M | Open |
How Many Employees Work at Health Rise Pharma India?
Unlock and access historical data on people associated with Health Rise Pharma India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Health Rise Pharma India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Health Rise Pharma India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
